Clinical Trial Update: The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial updating the efficacy and safety of fluzoparib plus irinotecan as second-line therapy in metastatic colorectal cancer with homologous recombinatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fluzoparib (fluzoparib)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Fudan University | Conditions: Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN